Chang, T. Et Al. 2006. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901). 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , (Massachusetts, United States Of America).

Chang, T., Chao, Y., Kaymakoglu, S., Cheinquer, H., Pessoa, M., Gish, R., ... Poordad, F.(2006). Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901) . 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America

Chang, Ting-Tsung Et Al. "Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)," 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 2006

Chang, Ting-Tsung Et Al. "Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)." 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America, 2006

Chang, T. Et Al. (2006) . "Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)." 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America.

@conferencepaper{conferencepaper, author={Ting-Tsung Chang Et Al. }, title={Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)}, congress name={57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases}, city={Massachusetts}, country={United States Of America}, year={2006}}